Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Conditions
Interventions
Copanlisib
Fulvestrant
Locations
7
United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
NYP/Weill Cornell Medical Center
New York, New York, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
University of Texas Medical Branch
Galveston, Texas, United States
Start Date
February 13, 2019
Primary Completion Date
February 19, 2022
Completion Date
February 19, 2022
Last Updated
September 25, 2023
NCT06492759
NCT05422794
NCT06500455
NCT03723928
NCT04704661
NCT05673200
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions